PCNU in the treatment of recurrent medulloblastoma and ependymoma -A POG study

Abdelsalam H. Ragab, Peter Burger, Solomon Badnitsky, Jeffrey Krischer, Jan Van Eys

Research output: Contribution to journalArticle

Abstract

Seventeen children with recurrent medulloblastoma and ependymoma received PCNU (100 mg/m2) in a Phase 11 trial. Response was evaluated by CAT scan. There were no responses. Administration of PCNU was associated with significant thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)341-342
Number of pages2
JournalJournal of neuro-oncology
Volume3
Issue number4
DOIs
StatePublished - Dec 1 1986

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'PCNU in the treatment of recurrent medulloblastoma and ependymoma -A POG study'. Together they form a unique fingerprint.

  • Cite this

    Ragab, A. H., Burger, P., Badnitsky, S., Krischer, J., & Van Eys, J. (1986). PCNU in the treatment of recurrent medulloblastoma and ependymoma -A POG study. Journal of neuro-oncology, 3(4), 341-342. https://doi.org/10.1007/BF00165583